Product nameAnti-Matriptase 2 antibody - Catalytic domain
See all Matriptase 2 primary antibodies
DescriptionRabbit polyclonal to Matriptase 2 - Catalytic domain
Specificityab56182 reacts with human Matripase 2 (TMPRSS6), and does not react with the other TMPRSSs. ab56182 recognizes all but the 2 truncated forms of human Matripase 2.
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Synthetic peptide based on the catalytic domain of Matriptase 2 (Human)
Storage instructionsShipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferpH: 7.40
Preservative: 0.05% Sodium azide
Constituents: 50% Glycerol, 2.9% Sodium chloride, PBS
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab56182 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Note: Glycosylation and other posttranslational modifications make matriptase 2 run at higher than expected mass on reduced SDS PAGE gels.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionSerine protease which hydrolyzes a range of proteins including type I collagen, fibronectin and fibrinogen. Can also activate urokinase-type plasminogen activator with low efficiency. May play a specialized role in matrix remodeling processes in liver. Required to sense iron deficiency. Overexpression suppresses activation of the HAMP promoter.
Tissue specificityLiver specific.
Involvement in diseaseDefects in TMPRSS6 are the cause of iron-refractory iron deficiency anemia (IRIDA) [MIM:206200]; also known as hypochromic microcytic anemia with defect in iron metabolism or hereditary iron-handling disorder or pseudo-iron-deficiency anemia. Key features include congenital hypochromic microcytic anemia, very low mean corpuscular erythrocyte volume, low transferrin saturation, abnormal iron absorption characterized by no hematologic improvement following treatment with oral iron, and abnormal iron utilization characterized by a sluggish, incomplete response to parenteral iron.
Sequence similaritiesBelongs to the peptidase S1 family.
Contains 2 CUB domains.
Contains 3 LDL-receptor class A domains.
Contains 1 peptidase S1 domain.
DomainCytoplasmic domain mediates HAMP suppression via proximal promoter element(s).
Cellular localizationCell membrane.
- Information by UniProt
- IRIDA antibody
- Matriptase-2 antibody
- Membrane bound mosaic serine proteinase matriptase 2 antibody
This product has been referenced in:
- Gurieva I et al. Erythropoietin administration increases splenic erythroferrone protein content and liver TMPRSS6 protein content in rats. Blood Cells Mol Dis 64:1-7 (2017). WB ; Rat . Read more (PubMed: 28282554) »
- Frýdlová J et al. Effect of Erythropoietin, Iron Deficiency and Iron Overload on Liver Matriptase-2 (TMPRSS6) Protein Content in Mice and Rats. PLoS One 11:e0148540 (2016). WB . Read more (PubMed: 26845567) »